EXCELLATM First-in-Man (FIM) study: Safety and efficacy of novolimus-eluting stent in de novo coronary lesions

EuroIntervention

Volumn 4, Issue 1, 2008, Pages 53-58

  Ribamar Costa, J ^a   Abizaid, Alexandre ^a   Feres, Fausto ^a   Costa, Ricardo ^a   Seixas, Ana Cristina ^a   Maia, Felipe ^a   Abizaid, Andrea ^a   Tanajura, Luis Fernando ^a   Staico, Rodolfo ^a   Siqueira, Dimytri ^a   Meredith, Lynn ^b   Bhat, Vinayak ^e   Yan, John ^b   Ormiston, John ^c   Sousa, Amanda G M R ^a   Fitzgerald, Peter ^d   Eduardo Sousa, J ^a  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^b Elixir Medical   (United States)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e NONE

Author keywords

Drug eluting stent; First in man; Novolimus; PCI

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NOVOLIMUS; RAPAMYCIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CHROMIUM DERIVATIVE; DRUG DERIVATIVE; MACROLIDE;

ADULT; ARTICLE; BLOOD VESSEL DIAMETER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CORONARY ANGIOGRAPHY; CORONARY ARTERY; CORONARY ARTERY OBSTRUCTION; DEVICE SAFETY; DUAL ANTIPLATELET THERAPY; FEMALE; FOLLOW UP; HUMAN; IN STENT LATE LUMEN LOSS; INTRAVASCULAR ULTRASOUND; MAJOR ADVERSE CARDIAC EVENT; MALE; NEOINTIMA; NEOINTIMAL HYPERPLASIA; AGED; ANGIOCARDIOGRAPHY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; FEASIBILITY STUDY; MIDDLE AGED; RADIOGRAPHY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBIOTICS, ANTINEOPLASTIC; CHROMIUM ALLOYS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACROLIDES; MALE; MIDDLE AGED; SIROLIMUS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 59249105164     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/eijv4i1a10     Document Type: Article

References (14)

1. Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW, Sousa AG. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation. 2005 May 10;111(18):2326-9.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003 Oct 2;349(14):1315-23.
3. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME; TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003 Aug 19;108(7):788-94.
4. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004 Jan 15;350(3):221-31.
5. Feres F, Costa JR Jr, Abizaid A. Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv. 2006 Jul;68(1):83-8.
6. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, Williams DO. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007 May 9;297(18):1992-2000.
7. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L; SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007 Mar 8;356(10):1009-19.
8. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001 Jan 16;103(2):192-5.
9. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006 Aug 22;114(8):798-806.
10. Serruys PW, Ong ATL, FRACP; Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, MD; Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PC. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroInterv. 2005; 1:58-65.
11. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Bonan R, Popma JJ, Cutlip DE, Fitzgerald P, Prpic R, Kuntz RE, First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroInterv. 2005;1:157-164.
12. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003 Jan 7;107(1):38-42.
13. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME; TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003 Aug 19;108(7):788-94.
14. Tusuchida K, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, MD; Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Veldhof S, Dorange C, Serruys PW. One- year results of a durable-polymer everolimus eluting stent in de novo coronary narrowings (The SPIRIT First trial). EuroInterv. 2005;1:266-272.